Skip to main content

Table 2 The comparative analysis on quantitative parameter of ccRCC and AML.wovf

From: Differentiation of renal angiomyolipoma without visible fat from small clear cell renal cell carcinoma by using specific region of interest on contrast-enhanced CT: a new combination of quantitative tools

Parameter

ccRCC (n = 57)

AML.wovf (n = 28)

t/Z

P

Pre-contrast phase

AVT_PCP (1)

32.78 ± 6.50

38.33 ± 5.47

− 4.171

 < 0.001

AVT_PCP (2)

34.73 ± 6.08

40.17 ± 6.43

− 4.115

 < 0.001

AVT_PCP (3)

30.28 ± 5.78

32.72 ± 9.18

− 1.371

0.178

HDT_PCP

11.60 ± 2.42

12.78 ± 4.91

− 1.269

0.213

SHR_PCP

150.12 ± 38.98

166.87 ± 60.86

− 1.416

0.165

Corticomedullary phase

AVT_CMP (1)

166.15 ± 40.61

147.58 ± 27.16

2.735

0.008

NEV_CMP (1)

133.37 ± 40.30

108.94 ± 28.39

3.529

0.001

RER_CMP (1)

88.22 ± 19.03

76.23 ± 14.59

3.496

0.001

AVT_CMP (2)

216.91 ± 43.87

181.18 ± 32.67

4.596

 < 0.001

NEV_CMP (2)

182.31 ± 45.15

140.68 ± 33.75

5.191

 < 0.001

RER_CMP (2)

116.21 ± 17.48

89.39 ± 14.48

7.522

 < 0.001

AVT_CMP (3)

127.99 ± 41.55

115.54 ± 31.79

1.494

0.138

NEV_CMP (3)

95.47 ± 34.12

85.40 ± 29.43

1.524*

0.127

RER_CMP (3)

66.85 ± 19.44

60.75 ± 14.96

1.562

0.121

HDT_CMP

39.58 ± 8.38

29.04 ± 6.92

6.174

 < 0.001

SHR_CMP

412.11 ± 116.92

290.53 ± 85.78

5.224

 < 0.001

Nephrographic phase

AVT_NP (1)

108.05 ± 22.28

108.77 ± 21.26

− 0.039*

0.969

NEV_NP (1)

75.27 ± 22.51

70.13 ± 21.61

1.081

0.282

RER_NP (1)

72.84 ± 12.38

67.16 ± 7.94

2.802

0.006

AVT_NP (2)

129.11 ± 24.69

116.90 ± 21.80

2.390

0.019

NEV_NP (2)

94.25 ± 25.98

78.02 ± 26.48

2.903

0.005

RER_NP (2)

87.36 ± 12.75

71.83 ± 8.49

7.307

 < 0.001

AVT_NP (3)

92.89 ± 27.15

93.20 ± 23.71

− 0.054

0.957

NEV_NP (3)

62.67 ± 25.87

60.48 ± 21.26

0.941*

0.347

RER_NP (3)

62.52 ± 17.48

57.28 ± 10.16

1.917

0.058

HDT_NP

25.03 ± 5.86

20.19 ± 5.21

3.977

 < 0.001

SHR_NP

304.39 ± 80.20

259.94 ± 64.79

2.329*

0.020

Excretory phase

AVT_EP (1)

87.56 ± 16.61

87.72 ± 12.03

− 0.051

0.960

NEV_EP (1)

54.77 ± 17.10

49.07 ± 13.18

1.660

0.100

RER_EP (1)

63.73 ± 9.27

60.52 ± 10.64

1.550

0.124

AVT_EP (2)

101.46 ± 18.53

97.05 ± 14.63

1.178

0.242

NEV_EP (2)

66.86 ± 19.54

56.56 ± 18.08

2.518

0.013

RER_EP (2)

73.95 ± 10.30

65.74 ± 11.32

3.616

 < 0.001

AVT_EP (3)

80.49 ± 17.99

78.64 ± 19.51

0.468

0.641

NEV_EP (3)

50.67 ± 17.70

45.92 ± 16.21

1.637*

0.102

RER_EP (3)

57.88 ± 11.35

53.85 ± 11.32

1.663

0.099

HDT_EP

19.79 ± 4.72

16.00 ± 4.40

3.833

 < 0.001

SHR_EP

247.34 ± 66.58

204.87 ± 54.68

3.134

0.002

  1. ccRCC: clear cell renal cell carcinoma, AML.wovf: angiomyolipoma without visible fat
  2. PCP: pre-contrast phase, CMP: corticomedullary phase, NP: nephrographic phase, EP: excretory phase
  3. AVT: attenuation value of tumor, NEV: net enhancement value, RER: relative enhancement ratio, HDT: heterogeneous degree of tumor, SHR: standardized heterogeneous ratio
  4. (1): ROI (1), (2): ROI (2), (3): ROI (3)
  5. *: Z value
  6. Data of AVT, HDT and NEV are means ± standard deviations in Hounsfield units. Data of RER and SHR are means ± standard deviations in percentage ratio
  7. The Mann–Whitney U test was applied in the analysis of AVT_NP (1), NEV_CMP (3), NEV_NP (3), SHR_NP and NEV_EP (3) comparison, the independent sample t-test was applied in the rest of the comparisons